Supergenics Share Price

03033

MYL03033O007

Biotechnology & Medical Research

Market Closed - BURSA MALAYSIA Other stock markets 08:50:01 30/12/2025 GMT			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

04-29	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
03033 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	29.11M 7.12M 6.24M 5.75M 5.39M 10.1M 672M 10.31M 69.17M 26.76M 332M 26.74M 26.15M 1.15B	P/E 2024	-9.45x	P/E 2025	-8.61x
Enterprise Value	32.5M 7.95M 6.97M 6.43M 6.02M 11.28M 750M 11.52M 77.24M 29.89M 371M 29.86M 29.2M 1.29B	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

04-29	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-05	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
29/08/25	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/08/25	Supergenics fixes issue price at 0.27 RGT per share	RE
12/08/25	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
21/03/25	Supergenics Berhad Announces Change of Registered Office Address	CI
28/02/25	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/08/24	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/04/24	Supergenics Seeks More Time to Complete Private Share Placement	MT
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05/01/24	41,850,000 Ordinary Shares of Supergenics Berhad are subject to a Lock-Up Agreement Ending on 6-JAN-2024.	CI

1 year	0.2	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	23/04/2019
Yuet Chyn Wong SEC	Corporate Secretary	-	01/06/2022

Director	Title	Age	Since
Fun Kim Ng BRD	Director/Board Member	60	23/04/2019
Bii Chau Tan BRD	Director/Board Member	48	23/04/2019
Kiat Yang Chan BRD	Director/Board Member	46	27/01/2022

Supergenics Share Price

Stocks

03033

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news : Supergenics

Quotes and Performance

Course Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	-16.67%	+13.64%	7.07M
LONZA GROUP AG	-0.48%	+7.20%	-5.08%	+2.45%	46.36B
REVOLUTION MEDICINES, INC.	+0.76%	+7.90%	+377.35%	+619.38%	37.88B
IQVIA HOLDINGS INC.	+1.72%	+12.76%	+19.64%	-11.50%	31.12B
BEONE MEDICINES AG	+0.99%	+2.01%	+8.94%	+53.95%	30.61B
CELLTRION, INC.	-4.16%	-4.44%	+8.53%	+16.06%	24.69B
ASCENDIS PHARMA A/S	-0.90%	+13.46%	-	-	16.25B
MEDPACE HOLDINGS, INC.	+0.71%	+15.02%	+70.82%	+132.81%	14.85B
EUROFINS SCIENTIFIC SE	+1.00%	+10.30%	+13.31%	+22.84%	13.58B
IONIS PHARMACEUTICALS, INC.	+2.73%	+5.60%	+101.46%	+104.96%	12.95B
Average	+2.38%	+7.07%	+64.26%	+106.07%	22.83B
Weighted average by Cap.	+0.08%	+7.66%	+83.47%	+136.32%

	2024	2025
Net sales	5.32M 1.3M 1.14M 1.05M 985K 1.85M 123M 1.89M 12.65M 4.89M 60.69M 4.89M 4.78M 210M	5.63M 1.38M 1.21M 1.11M 1.04M 1.95M 130M 1.99M 13.37M 5.17M 64.16M 5.17M 5.05M 222M
Net income	-7.28M -1.78M -1.56M -1.44M -1.35M -2.53M -168M -2.58M -17.3M -6.69M -83.04M -6.69M -6.54M -288M	-3.37M -823K -722K -665K -623K -1.17M -77.67M -1.19M -8M -3.09M -38.38M -3.09M -3.02M -133M
Net Debt	4.48M 1.1M 960K 885K 829K 1.55M 103M 1.59M 10.64M 4.12M 51.06M 4.11M 4.02M 177M	3.39M 830K 728K 671K 628K 1.18M 78.32M 1.2M 8.07M 3.12M 38.71M 3.12M 3.05M 134M

1 day	+21.95%
6 months	+21.95%